Pinned Tweet
意識のソースコード最終章。
新しい精神医学
サイケデリック治療を日本で実装する上で、日本の独自性について語っています。
最終章では特に
・MAPSの挫折から学んだ「体験統合」の重要性
・AIには絶対にない「神秘体験」が人間の核心であること
・日本文化(禅・修験道など)を活かした相転移医学の可能性
を深掘りしました。
note.com/voidphrenia/n/n6015…
介入精神医学とは。
テクノロジーと意識科学の融合のような、サイバーパンク世界のイメージだな。
🔜 🧠
“We are about to enter the era of interventional psychiatry, transforming the field of psychiatry.” — Tom Insel, former NIMH Director, at a recent psychedelic science conference.
We have invested in many of these new modalities: transcranial focused ultrasound (Sanmai), minimally invasive deep brain stimulation and vagus nerve stimulation (Neurobionics), brain-computer-interfaces (Neuralink), auditory dream engineering (Dust), psychedelic-assisted therapy (atai/Lilly), and real-world-data collection for all (Osmind).
Insel also co-authored a Nature paper with Osmind defining the field: nature.com/articles/s44220-0…
+ summary: osmind.org/interventional-ps…
Interventional psychiatry companies:
• tFUS: Sanm.ai/technology
• Endovascular DBS: Neurobionics.io
• BCI: Neuralink.com
• Dream engineering: DUST.systems
• Psychedelics: ataibeckley.com
P.S. Underfunded: “From 2002-2013, the NIMH did not receive any funding applications for psychedelics. It was all funded and legitimized by philanthropy.”
P.S.S. Needed: “The World Health Organization (WHO) predicts that without significant changes, mental illness will cost the world economy $16t by 2030, making it the largest disease burden globally." — UBS: flic.kr/p/2jcRcoS
We need significant changes.
Dr.Void/Norihide Ensako retweeted
This morning, Compass Pathways shared its Q3 2026 results, which included an update on its COMP360 psilocybin for treatment-resistant depression (TRD) new drug application (NDA) submission.
“Final NDA submission nearing completion”, the release states, “and will be filed in the next two weeks.”
Dr.Void/Norihide Ensako retweeted
We could see as many as four psychedelics approved for mental health conditions by the end of 2027:
- Psilocybin for TRD
- Psilocybin for MDD
- MDMA for PTSD
- LSD for GAD
Dr.Void/Norihide Ensako retweeted
第33回多文化間精神医学会学術総会は、2026年12月5日(土)~6日(日)@慶應義塾大学・三田キャンパス
jstp33.notion.site/33-2ca858…
第33回多文化間精神医学会学術総会
基調講演
「精神展開剤がひらく精神医学の新たな地平:臨床、脳科学、文化の交差点から」
jstp33.notion.site/33-2ca858…
Dr.Void/Norihide Ensako retweeted
Usona Instituteがうつ病向けシロシビンの新薬申請をFDAに提出。現在審査中の精神展開剤の新薬申請はこれで2件目となり、優先審査券により2026年末〜2027年初頭に承認可否が判断される可能性もある、とのことです。
なお、我々の臨床試験では、非営利団体であるUsonaの製剤を使用しています。
Nonprofit psychedelic research organisation Usona Institute has completed its submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) concerning its psilocybin candidate for major depressive disorder (MDD), Psychedelic Alpha understands.
It means it’s the second psychedelic NDA under review by the agency at present, after we reported that Resilient Pharmaceuticals (formerly Lykos Therapeutics) refiled its MDMA for PTSD application in the summer. It also means that FDA could hand down a decision on a psychedelic application in late 2026, if the most optimistic timelines hold, or very early in the new year, given the fact that Usona, like Compass Pathways, is in receipt of a Commissioner’s National Priority Voucher (CNPV) that aims to return a decision to a developer within two months.
In our latest, we review the context surrounding Usona’s program and application, and what it might mean for its chief competitor, Compass, a for-profit psilocybin drug developer that is planning to submit its own NDA, for treatment-resistant depression (TRD), imminently.
Read now on our website: psychedelicalpha.com/news/us…
Dr.Void/Norihide Ensako retweeted
Under pressure from Israeli prime minister Benjamin Netanyahu, the Trump administration may be within days of launching a nuclear strike on Iran. The target would be Pickax Mountain in central Iran, where Israeli intelligence claims the Iranian government has restarted its nuclear enrichment program. No conventional weapon in the American arsenal can penetrate 300 feet of solid granite to destroy the tunnels where enrichment is supposedly taking place. The only military option is a nuclear strike. Netanyahu has been pushing hard for one. “Bibi calls Trump about it every day,” says an informed observer.
Netanyahu is cornered and desperate. After last week’s election results, he can’t form a government unless Trump intervenes directly in Israeli politics and brokers a deal with other parties that gives Netanyahu 61 seats in the Knesset. Otherwise, he is out as prime minister and on his way to ignominy, investigations and possibly jail. Netanyahu must stay close to Trump. He needs this war.
To that end, he’s applied maximum pressure to his closest allies in the administration, including Secretary of Defense Pete Hegseth and CENTCOM commander Brad Cooper. Both oppose a negotiated settlement to the war they’ve so grievously mismanaged; both are pushing to restart major combat operations. Secretary of State Marco Rubio and CIA director John Ratcliffe are also following Netanyahu’s lead, as are leaders of the Democratic Party. In a recent meeting on the subject, former president Barack Obama said he opposes the current Iran peace deal being drafted in Doha.
The rest of America’s longtime allies in the Middle East are terrified by the prospect of more war. On September 27th, Netanyahu flew secretly to Abu Dhabi to enlist the UAE in his lobbying effort for a final attack on Iran. The Emiratis refused. After eight months of conflict, Gulf economies are teetering. So are global energy and fertilizer markets. They won’t recover soon. Globally, there are a total of about 850 supertankers used to transport oil from producers to the rest of the world. In October alone, 11 of them were badly damaged in Hormuz. At this pace, a global depression is imminent. A nuclear strike would radically accelerate the destruction. Fallout from a ground explosion at Pickax Mountain would contaminate the Persian Gulf, poisoning the water supply for 100 million people.
And those are just some of the immediate consequences for the region. The rest of the world is every bit as exposed. No country other than the United States has ever used a nuclear weapon in war. Some would like to. An American nuclear attack on Iran would set a new precedent. The Russians have already told at least two other governments that an American nuclear strike on Iran would free them to use nuclear weapons against Ukraine. Pakistan and India would be tempted to do the same against each other, as would North Korea against Seoul. After the first nuclear strike, World War Three is inevitable. That war would be short and final.
We’ve been sleepwalking toward this moment for months. Since February, the administration has quietly rewritten America’s nuclear doctrine to make first use of so-called “battlefield nukes” easier and therefore more likely. No one in Washington in either party seems bothered by this. Now we’re on the brink of it.
Close observers say Trump is likely to decide by next weekend whether or not to use nuclear weapons. That would be November 7, six days from now. To his credit, he’s hesitating. At the moment, Trump is listening to his vice president, JD Vance, and to his envoy and friend Steve Witkoff, both of whom argue a deal with Iran can be made.
They’re right, though it won’t be simple. The Iranians are famously frustrating to negotiate with under any circumstances, and elements of that government have become more radical since Ayatollah Ali Khamenei and his family were killed in February. After decades of isolation, even relatively moderate Iranian leaders seem confused by how decisions are made in the West. (There is a widespread belief in Tehran, for example, that the United States government controls Israel.) But overall, people who have spoken to decision-makers in Iran say there is consensus there that more war is bad for everyone and a deal is worth making.
One group that hasn’t been consulted so far is the global population — the hundreds of millions of people who will be killed along with their children if Trump is pushed by Netanyahu into launching a nuclear strike next week. Now would be the time for them to speak up.
Dr.Void/Norihide Ensako retweeted
オレキシン受容体拮抗薬のダリドレキサント(クービビック)が、小児ASDにおいて、不眠症状だけでなく、情動・行動・認知・日常生活機能にも改善をもたらす可能性が示された。今後、ASD児を対象とした臨床試験が進められる予定。クービビックは現在成人の不眠症治療薬として使用されている。今後の研究結果に期待したい。
idorsia.com/media/news/news-…
Dr.Void/Norihide Ensako retweeted
Nonprofit psychedelic research organisation Usona Institute has completed its submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) concerning its psilocybin candidate for major depressive disorder (MDD), Psychedelic Alpha understands.
It means it’s the second psychedelic NDA under review by the agency at present, after we reported that Resilient Pharmaceuticals (formerly Lykos Therapeutics) refiled its MDMA for PTSD application in the summer. It also means that FDA could hand down a decision on a psychedelic application in late 2026, if the most optimistic timelines hold, or very early in the new year, given the fact that Usona, like Compass Pathways, is in receipt of a Commissioner’s National Priority Voucher (CNPV) that aims to return a decision to a developer within two months.
In our latest, we review the context surrounding Usona’s program and application, and what it might mean for its chief competitor, Compass, a for-profit psilocybin drug developer that is planning to submit its own NDA, for treatment-resistant depression (TRD), imminently.
Read now on our website: psychedelicalpha.com/news/us…
岡山サイケデリック精神医療研究会(OIPI)の第9回の勉強会を開催しました。オンラインでの参加者も交えて、今日はMDMA支援療法についてデヴィッド・ナット先生の「幻覚剤と精神医学の最前線」をテキストに解説しました。
今週11/6(金)の第49回中国四国精神保健学会に、メキシコでのマジックマッシュルームでのPTSD治療を40年に渡ってフィールドワークされている、レジェンド宮西照夫先生を演者に迎えて講演が行われます。サイケデリック治療の関心の高さを実感します。
お近くの方は非常に貴重な機会です。是非ご参加下さい。
med-gakkai.jp/spn-cs66/
Dr.Void/Norihide Ensako retweeted
In 1967, a Harvard psychologist who had been fired for giving psychedelics to a student handed an old man in a blanket three tablets of LSD.
It was about nine times a normal dose.
According to the psychologist, nothing happened.
What the old man told him next changed his life, and years later sent a teenager to India who would go on to change all of ours.
The psychologist was Richard Alpert. The old man was Neem Karoli Baba, a Hindu saint his followers called Maharaj-ji.
Alpert had been a rising star at Harvard. With Timothy Leary, he ran experiments with psilocybin and LSD, which were still legal then. In 1963, Harvard fired him for giving psilocybin to an undergraduate.
He didn't stop, and for years he chased the same thing over and over. The doors would open, he would see something vast, and then he would come down, every single time.
In 1967 he went to India, more as a tourist than a pilgrim. A young American seeker led him into the Himalayan foothills, to a small temple and an old man in a blanket.
The night before, Alpert had been outside under the stars, thinking about his mother. She had died not long before.
The old man looked at him and started talking about it. Then he named the organ that had killed her, her spleen.
Alpert had told no one in India.
Something in him broke open. He cried, and couldn't stop.
The next day, Maharaj-ji asked for "the medicine." Alpert handed him the pills and watched him swallow them. He waited for the old man to fly.
Nothing seemed to happen to him at all.
Afterwards, he told Alpert that the state he had been chasing could be reached through meditation. And that he could live in it.
Alpert stayed, and Maharaj-ji gave him a new name, Ram Dass, servant of God.
Back in America, he wrote a book. Around ten publishers turned it down. A small spiritual community in New Mexico printed it instead.
It was called Be Here Now. It went on to sell more than two million copies.
But here is the part almost nobody knows.
One of its readers was a teenager in California. He later said the book transformed him and many of his friends. In 1974, at 19, he travelled to India to meet Maharaj-ji himself.
He arrived months too late. The old man had died the previous September.
The teenager's name was Steve Jobs.
Now the honest part. Skeptics have doubted the LSD story for decades. Ram Dass kept telling it anyway.
But the pills were never the point.
Think about what that means.
Alpert had spent years trying to get high enough to reach something. Every time, he came back down. The old man showed him it was never up there. It was what's left when the chasing stops.
Most of us are still chasing a state.
The retreat high.
The breakthrough.
The day it finally clicks for good.
And every time, we come back down.
In 1967, a Harvard psychologist went to India looking for a state he could stay in.
He came home with three words.
Be here now.
Dr.Void/Norihide Ensako retweeted
$CMPS $DFTX $HELP
“The future of psychedelics is looking bright, after some dark times. Just two years ago, the US Food and Drug Administration (FDA) rejected an application to use MDMA — the active ingredient in the party drug ecstasy — to treat post-traumatic stress disorder. With that refusal, the whole field seemed to stall. But now, billion-dollar investments and more clinical-trial data suggest that the field is forging ahead.
Lykos’s studies were “guinea pigs” for the industry, says Emma Wille, an analyst at business-intelligence provider Citeline in New York City. “Now, companies know more about what will make a good data-submission package.
Why such persistence in the pursuit of psychedelic therapies? Researchers partially credit increasingly clear guidance from regulators worldwide on how these treatments should be studied and used. Even in the United States, where regulatory teams in the FDA have been thinned by layoffs, psychedelics are still a priority. “Where there’s a governmental will, there’s a governmental way,” says Yehuda.
Definium Therapeutics, based in New York City, released results in August and September from late-stage studies of its LSD-based pill, showing a significant reduction in symptoms of generalized anxiety disorder.
And many are moving forwards with applications. Resilient resubmitted a new-drug application this year. Meanwhile, Compass Pathways has announced positive results from two late-stage trials of a psilocybin therapy for treatment-resistant depression. “It does look as though it’s inevitable that they will get the license”, says Robin Carhart-Harris, a neuroscientist and psychopharmacologist at the University of California, San Francisco.
The US government seems to anticipate movement on psychedelics. An August report from the US Substance Abuse and Mental Health Services Administration in Rockville, Maryland, urges states to prepare for possible FDA approval of psychedelic therapies by, among other recommendations, building the necessary health-system infrastructure to deliver such treatments.”
Researchers are optimistic about psychedelic drugs as potential treatments for depression and mood disorders, despite pushback having stalled the field
go.nature.com/4e1WDEM
Dr.Void/Norihide Ensako retweeted
No way this is real 🤯
Ancient South Americans were taking psychedelics...
THROUGH THEIR BUTTS?!
Archaeologists examined 25 ancient tubes, some made from bird bones, found around the Atacama Desert.
And on one of them, they discovered:
• Traces of human feces
• Bufotenine, a psychoactive compound
Which confirmed it was actually used for:
A PSYCHEDELIC ENEMA.
This was over 1,000 years ago.
Imagine being the archaeologist who had to explain that discovery 😂
Dr.Void/Norihide Ensako retweeted
哲学者ジル・ドゥルーズに師事し、刑事弁護士でもあった異色のクリエイターであり、デザイナーのリック・オウエンスとともに〈Owenscorp〉を設立運営するミシェル・ラミーと池田亮司によるコラボ作。池田の極度に精緻な電子音響と、ラミーの個性的で存在感のある声が交差 meditations.jp/products/mich…
Dr.Void/Norihide Ensako retweeted
No way this is real 🤯
Ancient South Americans were taking psychedelics...
THROUGH THEIR BUTTS?!
Archaeologists examined 25 ancient tubes, some made from bird bones, found around the Atacama Desert.
And on one of them, they discovered:
• Traces of human feces
• Bufotenine, a psychoactive compound
Which confirmed it was actually used for:
A PSYCHEDELIC ENEMA.
This was over 1,000 years ago.
Imagine being the archaeologist who had to explain that discovery 😂
Dr.Void/Norihide Ensako retweeted
独自の世界を探求する異色の精神科医、遠迫憲英先生に、ペルーのリトリート施設での、外国人向けに整備されたアヤワスカ儀礼の体験談を伺いました。
サイケデリックスには統合失調症を引き起こすリスクがあるというのでは?という私の問いに対し、遠迫先生は、精神科医が統合失調症を疑似体験することには意味があるのだ、と切り返しています。1950年代のLSD研究に通じるものがあります。
【アヤワスカ体験談 Part2】 Part1に引き続き、明治大学情報コミュニケーション学部准教授の蛭川立先生と、岡山県でHIKARI CLINICを開業されている精神科医の遠追憲英先生のお二人が南米で経験されたアヤワスカのセッション中の様子について貴重なお話をして頂きました。
youtu.be/FAlFpfy1QV4
Dr.Void/Norihide Ensako retweeted
岡山の心療内科 HIKARI CLINICで「準備・体験・統合」を軸にしたケタミン支援療法(KAP)を開始
prtimes.jp/main/html/rd/p/00…
医療法人啓光会 HIKARI CLINIC(岡山市北区、理事長・院長:遠迫憲英)は、2026年9月より、うつ病を対象としたケタミン支援療法(Ketamine-Assisted Psychotherapy、以下 KAP...
Dr.Void/Norihide Ensako retweeted
【アヤワスカ体験談 Part1】
明治大学情報コミュニケーション学部准教授の蛭川立先生と、岡山県でHIKARI CLINICを開業されている精神科医の遠追憲英先生のお二人をゲストとしてお招きし、お二人が経験されたアヤワスカの体験談やその医療的な活用について深く掘り下げます。
youtu.be/ewMAlXiOMXo
Dr.Void/Norihide Ensako retweeted
【アヤワスカ体験談 Part2】 Part1に引き続き、明治大学情報コミュニケーション学部准教授の蛭川立先生と、岡山県でHIKARI CLINICを開業されている精神科医の遠追憲英先生のお二人が南米で経験されたアヤワスカのセッション中の様子について貴重なお話をして頂きました。
youtu.be/FAlFpfy1QV4
Dr.Void/Norihide Ensako retweeted
Remember that case that went viral a few months ago about the 80 yo woman with advanced Alzheimer’s who took a hero’s dose (5g) of psilocybin mushrooms and seemingly reversed her disease?
Well @PsychoMechanics and I dove into the research, and while it’s still very early days, there’s compelling biological explanations for how magic mushrooms could play a role in both treating and preventing cognitive decline/dementia.
Here’s how:
Structural neuroplasticity: 5-HT2A receptor activation appears to promote dendritic growth, synaptogenesis, and plasticity-related signaling. Very relevant in a disease characterized by progressive synaptic loss.
Apical hypercontextualization: Psilocybin may amplify signaling through layer V pyramidal neuron apical dendrites, increasing the brain’s sensitivity to contextual information and potentially enabling dysfunctional predictive models to be updated.
Neuroinflammation + neuroprotection: Serotonergic psychedelic signaling may modulate inflammatory pathways and cellular stress responses implicated in neurodegeneration.
Disease-modifying behavior change: Most compellingly (to me), psilocybin can open up a critical learning window in which entrenched behaviors become more malleable. This can help modify upstream dementia risk factors including physical inactivity, depression, smoking, harmful alcohol use, and social isolation.
I made a Youtube video explaining these concepts for a general audience. Check it out, and please share with anyone who wants to prevent cognitive decline!






































